Sorafenib as Effective Treatment for Newly Diagnosed AML in Younger Patients

Summary

Acute myeloid leukemia, a common form of leukemia with a high mortality rate, is difficult to treat. In the SORAML trial, sorafenib, a multikinase inhibitor, prolonged event-free and relapse-free survival compared with a placebo in younger patients with acute myeloid leukemia. However, this benefit was accompanied by a higher rate of infections and bleeding.

  • overall survival
  • event free survival
  • relapse free survival
  • infection
  • bleeding
  • sorafenib
  • placebo
  • Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
  • SORAML
  • NCT00893373
View Full Text